Acute myeloid leukemia (AML) is characterized by impaired differentiation and indefinite
proliferation of abnormal myeloid progenitors. Although differentiating agents were deemed …

The search for molecules to be targeted that are involved in apoptosis resistance/increased
survival and pathogenesis of onco-hematological malignancies is ongoing since these …

Several new therapeutic strategies are now considered for acute myeloid leukemia (AML)
patients unfit for intensive chemotherapy, including modulation of protein lysine acetylation …

Differentiation therapies using all-trans retinoic acid (ATRA) are highly efficient at treating
acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). However …

Although TP53 mutations are rare in acute myeloid leukemia (AML), wild type p53 function is
habitually annulled through overexpression of MDM2 or through various mechanisms …

The success of all-trans retinoic acid (ATRA) therapy in acute promeylocytic leukemia (APL)
has spawned numerous attempts to translate the paradigm of differentiation therapy to non …

The diversity of natural compounds is essential for their mechanism of action. The source,
structures and structure activity relationship of natural compounds contributed to the …

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the
accumulation of immature myeloid progenitor cells in the bone marrow, compromising of …

Introduction: Splenic tyrosine kinase (SYK) is a non-receptor tyrosine kinase. It is important
for downstream signaling from several cell surface receptors, including Fc receptors …

Background A large proportion of patients with acute myeloid leukemia (AML) are not fit for
intensive and potentially curative therapy due to advanced age or comorbidity. Previous …